BioLineRX Ltd. · TASE:BLRX

BioLineRX — Investor Presentation (September 2014)

37 slides from BioLineRX's investor presentation, September 2014

  1. Slide 1: Company Presentation

    Slide 1: Company Presentation

    Company Presentation September 2014

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u

  3. Slide 3: BioLineRx - General

    Slide 3: BioLineRx - General

    BioLineRx - General • Founded in 2003 by Teva and other key players in Israeli Life Sciences industry • Bridge “development gap” for Israeli assets – Leverage carefully selected early-stage technology, primarily at academia level, following proof of concept in animals (at a minimum) – Invest 3-6 yea

  4. Slide 4: BioLineRx Value Proposition

    Slide 4: BioLineRx Value Proposition

    BioLineRx Value Proposition Extensive deal-flow funnel • Outstanding access to early assets via expert in-licensing team constantly monitoring life science innovations in Israel and abroad • In-licensing efforts guided by open dialogue with R&D and BD divisions Expedited development • Multidisciplin

  5. Slide 5: Long Term Relationships with Israeli Institutions

    Slide 5: Long Term Relationships with Israeli Institutions

    Long Term Relationships with Israeli Institutions Technion Rambam Medical Center Academic Institutes Haifa Tel Aviv University Medical Centers Sheba Medical Center Tel-Aviv Hebrew University Rehovot Jerusalem Be’er Sheva Hadassah Medical Center Weizmann Institute Ben-Gurion University Sourasky Medic

  6. Slide 6: Main Pipeline Assets

    Slide 6: Main Pipeline Assets

    Main Pipeline Assets Pre-Clinical Partners PROJECT INDICATION LEAD DEVELOPMENT PROGRAMS AML Stem cell mobilization CML BL-7010 Celiac disease ADDITIONAL DEVELOPMENT PROGRAMS Skin lesions Inflammatory bowel disease Severe asthma/allergies BL-1110 Neuropathic pain/scleroderma PROGRAMS PARTNERED OR IN

  7. Slide 7: Lead Development Programs

    Slide 7: Lead Development Programs

    LEAD DEVELOPMENT PROGRAMS 7

  8. Slide 8: BL-8040: Best-in-class CXCR4 antagonist for hematological cancers

    Slide 8: BL-8040: Best-in-class CXCR4 antagonist for hematological cancers

    BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF HEMATOLOGICAL CANCERS 8

  9. Slide 9: BL-8040 Highlights

    Slide 9: BL-8040 Highlights

    BL-8040 Highlights • Indications: Acute myeloid leukemia (AML) & other hematological cancers – Orphan designation received from FDA for both AML and stem-cell mobilization • Mode of Action: CXCR4 antagonism – CXCR4 over-expressed in >70% of tumors, and correlates with disease severity. • Status: Pha

  10. Slide 10: AML – Treatment and Unmet Medical Need

    Slide 10: AML – Treatment and Unmet Medical Need

    AML – Treatment and Unmet Medical Need • AML is most common acute leukemia in adults – Over 60,000 new cases recorded worldwide in 2010, growing to 130,000 by 2020 – 14,000 cases of AML diagnosed in the US in 2012 – Majority of AML patients relapse and require repeated treatment cycles • AML has poo

  11. Slide 11: BL-8040 Mechanism Of Action

    Slide 11: BL-8040 Mechanism Of Action

    BL-8040 Mechanism Of Action • Binds CXCR4 with high affinity (1-2 nM) • Maintains extended inhibition of CXCR4 through long receptor occupancy (>24 hours) • Works as inverse agonist of CXCR4 • Induces apoptosis of tumor cells dependent on CXCR4 for survival • Increases sensitivity to anti-cancer age

  12. Slide 12: BL-8040 Superiority to Mozobil

    Slide 12: BL-8040 Superiority to Mozobil

    BL-8040 Superiority to Mozobil Mobilization BL-8040 12 mg/kg Mozobil 3.2 mg/kg Number of Neutrophils Time post BL-8040/Mozobil injection Cell Death 12

  13. Slide 13: Other Evidence of BL-8040's Superior Anti-Cancer Effect

    Slide 13: Other Evidence of BL-8040's Superior Anti-Cancer Effect

    Other Evidence of BL-8040’s Superior Anti-Cancer Effect BL-8040 (formerly BKT140) inhibits proliferation of Ramos cells compared with Mozobil (AMD3100) and BMS-936564 (MDX-1338) * Study was conducted by scientists from BMS * Kuhne MR, Clinical Cancer Research, 2012 13

  14. Slide 14: Summary of BL-8040 vs. Competitors

    Slide 14: Summary of BL-8040 vs. Competitors

    Summary of BL-8040 vs. Competitors BL-8040 Mozobil BMS-936564 (BKT-140) (Plerixafor/AMD3100) (MDX1338) Affinity with CXCR4 1-2 nM 84 nM 5nM MOA Inverse agonist Antagonist (partial agonist) Antagonist Extracellular domains in the Trans-membrane regions in Extracellular domains in the CXCR4 Binding si

  15. Slide 15: BL-8040 Platform – Clinical Development Program

    Slide 15: BL-8040 Platform – Clinical Development Program

    BL-8040 Platform – Clinical Development Program Pre-Clinical Phase I Phase II Phase III PROTOCOL INDICATION HEMATOLOGICAL MALIGNANCIES BL-8040.01 R/R AML Ongoing BL-8040.03 CML Investigator-initiated study STEM CELL MOBILIZATION BKTSC001 MM SC MOBILIZATION Completed BL-8040.02 SINGLE AGENT SC MOBILI

  16. Slide 16: Phase IIa - Treatment of r/r AML patients

    Slide 16: Phase IIa - Treatment of r/r AML patients

    Phase IIa - Treatment of r/r AML patients A phase IIa, multicenter, open-label study designed to evaluate safety and efficacy profile of repeated escalating doses of BL-8040 in adult subjects with relapsed or refractory acute myeloid leukemia Study design: – Dose escalation phase – 3+3 design, up to

  17. Slide 17: Partial Results in AML Phase II Study

    Slide 17: Partial Results in AML Phase II Study

    Partial Results in AML Phase II Study • Safe at all doses tested to date (0.5, 0.75 and 1mg/kg) • Substantial mobilization of cancer cells from BM to peripheral blood • Evidence for robust effect of cancer cell death Peripheral blood sample apoptosis assay • Completion of study expected in early 201

  18. Slide 18: BL-8040 Summary

    Slide 18: BL-8040 Summary

    BL-8040 Summary • CXCR4 is a validated target • BL-8040 has robust mobilization activity and apoptosis – Validated in preliminary data from Phase II study in AML, and Phase I/II study in multiple myeloma – BL-8040 has very favorable profile in comparison with leading CXCR4 antagonists • BL-8040 is a

  19. Slide 19: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease

    Slide 19: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease

    BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE 19

  20. Slide 20: BL-7010: Polymeric Binder for Celiac Disease

    Slide 20: BL-7010: Polymeric Binder for Celiac Disease

    BL-7010: Polymeric Binder for Celiac Disease • Indication: Celiac disease • Mode of Action: Non-absorbable polymer with high affinity to gliadins (immunogenic peptides contained in gluten) • Status: Phase I/II ongoing • Product Highlights – Prevents pathological damage to small intestine – Non-absor

  21. Slide 21: Celiac Disease – Large Unmet Medical Need

    Slide 21: Celiac Disease – Large Unmet Medical Need

    Celiac Disease – Large Unmet Medical Need • 1% of world’s population suffers from celiac disease – Number underestimated due to lack of awareness/diagnostic tools • Market projected to reach $8 billion by 2019 • No current pharmacological agents approved for celiac – Only treatment option is life-lo

  22. Slide 22: BL-7010 Prevents Formation of Gliadin's Immunogenic Peptides

    Slide 22: BL-7010 Prevents Formation of Gliadin's Immunogenic Peptides

    BL-7010 Prevents Formation of Gliadin’s Immunogenic Peptides Gluten Gluten BL-7010 Copolymer of sodium styrene sulfonate (SS) and 2-hydroxyethyl methacrylate (HEMA) Gliadin Enterocytes BL-7010 demonstrates distinguished specificity towards gliadin Small intestinal damage with loss of absorptive vill

  23. Slide 23: BL-7010 Maintains Normal Structure of GI

    Slide 23: BL-7010 Maintains Normal Structure of GI

    BL-7010 Maintains Normal Structure of GI Model: HLA-DQ8/HCD4 transgenic male mice sensitized to gliadin non-sensitized Gluten-sensitized Gluten-sensitized mice mice mice + BL-7010 Villus-to-crypt ratio 5.96 ± 1.23 2.58 ± 0.43 4.89 ± 1.51 23

  24. Slide 24: BL-7010 Clinical Program Overview

    Slide 24: BL-7010 Clinical Program Overview

    BL-7010 Clinical Program Overview • Phase I/II study in celiac patients – Consists of 2 parts: – Single ascending dose – 14 days repeated administration – Safety endpoints – 3 times per day – No efficacy endpoints – Safety w/o efficacy endpoints – Assessment of systemic exposure – Assessment of syst

  25. Slide 25: BL-7010 Clinical Program Overview (cont.)

    Slide 25: BL-7010 Clinical Program Overview (cont.)

    BL-7010 Clinical Program Overview (cont.) • Pivotal study in celiac patients expected to begin H1 2015 – 6-week repeated oral administration – Efficacy endpoints (primary and secondary) and safety endpoints • A pre-IND meeting with FDA is expected to take place in H1 2015 25

  26. Slide 26: BL-7010 Summary

    Slide 26: BL-7010 Summary

    BL-7010 Summary • Celiac disease is a huge unmet medical need – There are only a handful of clinical-stage programs in development • BL-7010 has a unique MOA – High-molecular-weight polymers – High affinity to gluten – Secreted through feces • Currently in Phase 1/2 pilot study – Compound is well to

  27. Slide 27: BL-1040: First-in-class myocardial implant

    Slide 27: BL-1040: First-in-class myocardial implant

    BL-1040: FIRST-IN-CLASS MYOCARDIAL IMPLANT FOR PREVENTION OF VENTRICULAR REMODELING FOLLOWING AMI Out-licensed to Bellerophon (f/k/a Ikaria) and being developed as Bioabsorbable Cardiac Matrix (BCM) 27

  28. Slide 28: BL-1040 Highlights

    Slide 28: BL-1040 Highlights

    BL-1040 Highlights • Indication: Cardiac remodeling post-AMI • Mode of Action: Provides support to ischemic tissue during healing • Status: CE Mark registration trial – completion expected in mid-2015 • Device designation (including FDA) • Partnered with Bellerophon BCM (f/k/a Ikaria) – Total deal s

  29. Slide 29: Unmet Medical Need

    Slide 29: Unmet Medical Need

    Unmet Medical Need Vessel occlusion Tissue damage Successfully treated with PCI and stents No sufficiently effective treatment for myocardial damage 29

  30. Slide 30: How Does BL-1040 Work?

    Slide 30: How Does BL-1040 Work?

    How Does BL-1040 Work? Arterial injection deposits Porcine AMI model, day 60 material into infarcted tissue Untreated BL-1040 Turns from liquid to gel on contact with infarcted tissue L L V V Gel-like scaffold provides mechanical support to damaged tissue • Dilated left ventricle • Normal size left

  31. Slide 31: Promising Results from Pilot Study

    Slide 31: Promising Results from Pilot Study

    Promising Results from Pilot Study • Designated as device by regulatory authorities (including FDA) • Pilot study in Europe – completed January 2010 – 27 patients, safety and preliminary efficacy in patients with primary MI at high risk for LV remodeling • 9 sites: 6 in Germany, 3 in Belgium • Trial

  32. Slide 32: BL-1040 Pivotal Clinical Development Program

    Slide 32: BL-1040 Pivotal Clinical Development Program

    BL-1040 Pivotal Clinical Development Program Pivotal CE Mark Registration trial progressing at full steam • Placebo controlled, total enrollment ~300 patients, six-month follow- up • ~80 sites currently active in nine countries (including 15 sites in US) • >200 patients enrolled to date • Endpoints:

  33. Slide 33: BL-1040 Summary

    Slide 33: BL-1040 Summary

    BL-1040 Summary • Huge unmet medical need – >$1 billion market • Designated as device in both US and Europe • Pilot study successfully completed – No safety or tolerability issues after six months of follow-up – Promising efficacy in comparison to historical data • CE mark registration study progres

  34. Slide 34: Corporate

    Slide 34: Corporate

    CORPORATE 34

  35. Slide 35: Financial and Corporate Summary

    Slide 35: Financial and Corporate Summary

    Financial and Corporate Summary Strong cash position • $33.1 million as of June 30, 2014 • Funds operational capital through end of 2016 • Expect to reach several value inflection points during this time Capital structure • Traded on NASDAQ and TASE (Symbol: BLRX) • 34 million shares outstanding; 40

  36. Slide 36: Major Milestones over next 12 Months

    Slide 36: Major Milestones over next 12 Months

    Major Milestones over next 12 Months 2014 BL-7010 (Celiac Disease) phase 1/2 completion BL-8040 (SC Mobilization) phase 1 initiation √ BL-8040 (AML) phase 2 partial results* BL-8040 (CML) phase 1/2 study initiation BL-1040 (AMI) complete CE mark study enrollment BL-8040 (SC Mobilization) phase 1 com

  37. Slide 37: Bench1o Bedoideto Patner

    Slide 37: Bench1o Bedoideto Patner

    Bench1o Bedoideto Patner BIOLINEM >< 37

Source: Internet Archive copy of biolinerx.com

More decks from BioLineRX Ltd.

All 37 BioLineRX decks